How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials-Reference-Cited by-同舟云学术

How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials

Published:2019-10 Issue: Volume:142 Page:68-75
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Santini Daniele,Galvano Antonio^ORCID,Pantano Francesco,Incorvaia Lorena,Rizzo Sergio,Vincenzi Bruno,Castellana Luisa,Giuliana Giovanna,Guadagni Fiorella,Toia Francesca,Tonini Giuseppe,Russo Antonio,Badalamenti Giuseppe,Bazan Viviana

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference20 articles.

1. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer;Van Poznak;J. Clin. Oncol.,2011

2. Management of cancer treatment-induced bone loss;Coleman;Nat. Rev. Rheumatol.,2013

3. Mechanisms of bone metastasis;Roodman;N. Engl. J. Med.,2004

4. Breast-cancer adjuvant therapy with zoledronic acid;Coleman;N. Engl. J. Med.,2011

5. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results;Coleman;Ann. Oncol.,2013

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management;Scientific Reports;2024-06-11

2. Efficacy and safety of bone management agents administered at 12 weeks vs. 4 weeks in patients with bone metastases: A systematic review;Journal of Oncology Pharmacy Practice;2023-10-09

3. Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw;Current Oncology;2022-03-05

4. Bone metastases—current status of bone-targeted treatments;Bone Cancer;2022

5. Quantitative bone single photon emission computed tomography analysis of the effects of duration of bisphosphonate administration on the parietal bone;Scientific Reports;2020-10-15